Skip to main content
Clinical Trials/NCT04165499
NCT04165499
Completed
Early Phase 1

Preliminary Study of Nutritional Intervention, Randomized, Double Blind, and Controlled Parallel Groups to Evaluate the Effect of Consuming a Combination of of Plant Extracts (BSL_EP026) on Serum Uric Acid in Hypeuricemic Subjects.

Biosearch S.A.1 site in 1 country34 target enrollmentNovember 11, 2019
ConditionsHyperuricemia

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Hyperuricemia
Sponsor
Biosearch S.A.
Enrollment
34
Locations
1
Primary Endpoint
Uric acid
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The objective of this study is to evaluate the effect of the combination of a combination of plant extracts (BSL_EP026) on blood and urine uricemia levels in individuals with levels at the limit of the values considered normal or moderately high.

Detailed Description

Hyperuricemia is an abnormally high level of uric acid in the blood, resulted because of an increased production of uric acid, decreased excretion of uric acid, or both. This can cause gout and nephrolithiasis, and it has also been related to metabolic syndrome, diabetes mellitus, cardiovascular disease and chronic kidney disease. Some plant extracts have diuretic activity that could contribute to improve uric acid excretion. This effect would lead to a decrease in uric acid plasma levels and, secondarily, to an action on its metabolic pathway of endogenous biogeneration. On the other hand, uric acid has a double reabsorption-elimination step in the renal tubules and the flavonoids of both extracts impede the processes of renal resorption promoting urinary elimination, in addition to increase the pH of the urine (higher than pH 5.8), which favors the non-precipitation or formation of urate stones. Finally, the routine (present in the used extracts) inhibit the uric acid formation pathway from purines, which would act synergistically. In this project, the effect of the intake of a combination plant extracts on uricemia levels will be studied.

Registry
clinicaltrials.gov
Start Date
November 11, 2019
End Date
March 20, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Biosearch S.A.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Blood uric acid levels greater than 7 mg/dL in men and 6 mg dL in women.
  • Accept freely to participate in the study and sign the informed consent document.

Exclusion Criteria

  • Having treatment that can affect uric acid levels.
  • Use of diuretics.
  • Follow a low purine diet.
  • Take a food supplement or drug that interferes with uric acid metabolism and renal system function.
  • Have an allergy to birch and/or orthosiphon or another component of the test products.
  • Low compliance expectation.

Outcomes

Primary Outcomes

Uric acid

Time Frame: 2 weeks

Uric acid in plasma

Secondary Outcomes

  • Blood pressure(2 weeks)
  • pH of urine(2 weeks)
  • Fractional clearance of urate (FCU)(2 weeks)
  • Uric acid in urine(2 weeks)

Study Sites (1)

Loading locations...

Similar Trials